16.95
price down icon7.48%   -1.37
after-market After Hours: 16.91 -0.04 -0.24%
loading
Immunovant Inc stock is traded at $16.95, with a volume of 4.51M. It is down -7.48% in the last 24 hours and up +7.62% over the past month. Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
See More
Previous Close:
$18.32
Open:
$16.32
24h Volume:
4.51M
Relative Volume:
3.56
Market Cap:
$2.90B
Revenue:
-
Net Income/Loss:
$-382.71M
P/E Ratio:
-6.4695
EPS:
-2.62
Net Cash Flow:
$-325.64M
1W Performance:
-5.36%
1M Performance:
+7.62%
6M Performance:
-26.46%
1Y Performance:
-39.03%
1-Day Range:
Value
$15.31
$17.31
1-Week Range:
Value
$15.31
$18.64
52-Week Range:
Value
$12.72
$34.47

Immunovant Inc Stock (IMVT) Company Profile

Name
Name
Immunovant Inc
Name
Phone
917-580-3099
Name
Address
320 WEST 37TH STREET, NEW YORK, NY
Name
Employee
362
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
IMVT's Discussions on Twitter

Compare IMVT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IMVT
Immunovant Inc
16.95 3.13B 0 -382.71M -325.64M -2.62
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-10-25 Resumed Goldman Neutral
Mar-03-25 Initiated Jefferies Hold
Jan-03-25 Downgrade Wolfe Research Outperform → Peer Perform
Oct-10-24 Resumed Raymond James Outperform
Oct-09-24 Reiterated Oppenheimer Outperform
Mar-28-24 Initiated Oppenheimer Outperform
Mar-13-24 Initiated Goldman Buy
Feb-20-24 Initiated JP Morgan Overweight
Feb-15-24 Initiated Wolfe Research Outperform
Dec-12-23 Initiated Deutsche Bank Buy
Oct-13-23 Upgrade UBS Neutral → Buy
Sep-26-23 Upgrade Raymond James Mkt Perform → Outperform
May-01-23 Initiated BofA Securities Buy
Apr-25-23 Initiated Citigroup Buy
Mar-31-23 Initiated Piper Sandler Overweight
Mar-30-23 Initiated Stifel Buy
Feb-15-23 Initiated Cantor Fitzgerald Overweight
Feb-13-23 Upgrade Guggenheim Neutral → Buy
Jan-03-23 Upgrade Wells Fargo Equal Weight → Overweight
Sep-26-22 Downgrade UBS Buy → Neutral
Dec-08-21 Initiated Wells Fargo Equal Weight
Aug-03-21 Downgrade Robert W. Baird Outperform → Neutral
Aug-02-21 Downgrade Credit Suisse Neutral → Underperform
Jun-01-21 Downgrade Guggenheim Buy → Neutral
Jun-01-21 Downgrade Stifel Buy → Hold
Oct-28-20 Initiated UBS Buy
Oct-12-20 Initiated Guggenheim Buy
Oct-08-20 Initiated Stifel Buy
Oct-02-20 Initiated Credit Suisse Outperform
Aug-26-20 Reiterated H.C. Wainwright Buy
Aug-25-20 Initiated Raymond James Outperform
Jul-29-20 Initiated H.C. Wainwright Buy
Feb-24-20 Initiated SVB Leerink Outperform
View All

Immunovant Inc Stock (IMVT) Latest News

pulisher
Jul 25, 2025

Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView

Jul 25, 2025
pulisher
Jul 25, 2025

Can Immunovant Inc. stock recover from recent declineHigh-profit stock alerts - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Is Immunovant Inc. a good long term investmentExceptional gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Immunovant Inc. stock priceHigh-profit stock alerts - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

What analysts say about Immunovant Inc. stockTremendous wealth creation - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Why Immunovant Inc. stock attracts strong analyst attentionFree Daily Stock Market Updates - Newser

Jul 24, 2025
pulisher
Jul 24, 2025

How high can Immunovant Inc. stock price go in 2025Free Smart Trading Workshop - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

Immunovant, Inc. (NASDAQ:IMVT) Shares Purchased by Arizona State Retirement System - Defense World

Jul 23, 2025
pulisher
Jul 23, 2025

Immunovant Inc. Stock Analysis and ForecastRecord-setting profit potential - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 19, 2025

Teacher Retirement System of Texas Buys 2,919 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Jul 19, 2025
pulisher
Jul 18, 2025

why immunovant inc. stock attracts strong analyst attentionFree Access to Community - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

September 19th Options Now Available For Immunovant (IMVT) - Nasdaq

Jul 17, 2025
pulisher
Jul 16, 2025

(IMVT) Trading Advice - news.stocktradersdaily.com

Jul 16, 2025
pulisher
Jul 16, 2025

All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Goldman Sachs Resumes Coverage of Immunovant (IMVT) with a Hold Rating - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High? - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Immunovant Inc. stock price move sharplyShort Squeeze Radar - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Immunovant Inc. stock performs during market volatilityFree Trading Strategy Suggestions - Newser

Jul 15, 2025
pulisher
Jul 13, 2025

Principal Financial Group Inc. Sells 31,255 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Jul 13, 2025
pulisher
Jul 12, 2025

The Goldman Sachs Group Upgrades Immunovant (NASDAQ:IMVT) to Hold - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

Immunovant (IMVT) chief technology officer Stout sells $26k in stock - Investing.com Australia

Jul 11, 2025
pulisher
Jul 10, 2025

Goldman Sachs resumes Immunovant stock coverage with Neutral rating By Investing.com - Investing.com Canada

Jul 10, 2025
pulisher
Jul 07, 2025

Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Jul 07, 2025
pulisher
Jul 07, 2025

Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Mirae Asset Global Investments Co. Ltd. - Defense World

Jul 07, 2025
pulisher
Jul 06, 2025

(IMVT) Technical Data - news.stocktradersdaily.com

Jul 06, 2025
pulisher
Jun 25, 2025

How to Take Advantage of moves in (IMVT) - news.stocktradersdaily.com

Jun 25, 2025
pulisher
Jun 23, 2025

Immunovant (NASDAQ:IMVT) Stock Updated Nasdaq Composite - Kalkine Media

Jun 23, 2025

Immunovant Inc Stock (IMVT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):